There are 2789 resources available
665P - Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101
Presenter: Marc-Oliver Grimm
Session: ePoster Display
666P - Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A
Presenter: David McDermott
Session: ePoster Display
667P - Cost effectiveness of immune checkpoint inhibitors in combination with targeted therapies in metastatic renal cell carcinoma
Presenter: Neil Mason
Session: ePoster Display
Resources:
Abstract
668P - Matching-adjusted indirect comparison (MAIC) of health-related quality of life (HRQoL) of nivolumab plus cabozantinib (N+C) vs pembrolizumab plus axitinib (P+A) in previously untreated advanced renal cell carcinoma (aRCC)
Presenter: Camillo Guglielmo Porta
Session: ePoster Display
669P - Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study
Presenter: Rustem Gafanov
Session: ePoster Display
670P - Cabozantinib associated with concomitant radiotherapy or a bone targeted agent (multimodal approach, results from the CABOREAL study post-hoc analysis)
Presenter: Marine Gross-Goupil
Session: ePoster Display
671P - Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from the 2020 Global Patient Survey from 41 countries
Presenter: Rachel Giles
Session: ePoster Display
672P - Real-world study of cabozantinib in patients with advanced renal cell carcinoma (aRCC) after VEGF-targeted therapy (CASSIOPE): Interim data for patients who had received prior nivolumab
Presenter: Giuseppe Procopio
Session: ePoster Display